TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29663160

Group type: EXPERIMENTAL
Intervention: Swallowing dysfunction (abnormal swallowing capacity)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Signs of aspiration (cough and voice change)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Risk of undernutrition
Number of subjects: 391
Study: 29663330

Group type: EXPERIMENTAL
Intervention: NIR-ICG imaging
Number of subjects: 504

Group type: COMPARATOR
Intervention: Standard operator visual assessment alone
Number of subjects: 504
Study: 29663523

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 0
Study: 29664050

Group type: EXPERIMENTAL
Intervention: High-level perceived stressfulness (HPS) of stressful life events (SLEs)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed by the 17-item Hamilton Depression Scale (HAMD-17)
Number of subjects: 1029
Study: 29664672

Group type: EXPERIMENTAL
Intervention: Primary care management of sleep apnea, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care for sleep apnea, details on dosage and duration not available
Number of subjects: 0
Study: 29664709

Group type: EXPERIMENTAL
Intervention: G1XCGD, a lentiviral vector for ex vivo gene therapy
Number of subjects: 0
Study: 29665034

Group type: EXPERIMENTAL
Intervention: NAFL (nonalcoholic fatty liver) prevalence assessment
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Altered glucose homeostasis in adolescents with NAFL
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Risk factors for NAFL incidence
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Predictors for resolution of NAFL at follow-up
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Model predictive performance with gene variants
Number of subjects: 503
Study: 29665842

Group type: EXPERIMENTAL
Intervention: Sensory re-learning in combination with task-specific training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task-specific training only (control group)
Number of subjects: 0
Study: 29665840

Group type: EXPERIMENTAL
Intervention: Cyclosporine A pretreatment (2.5 mg/kg) in deceased organ donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 29666047

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clinical status
Number of subjects: 84
Study: 29666122

Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of dexamethasone phosphate (1.2 mA/min at 0.4 mA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of dexamethasone phosphate
Number of subjects: 18
Study: 29666163

Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development-III (BSID III) cognitive score cutoff <70
Number of subjects: 2113

Group type: EXPERIMENTAL
Intervention: Neurologic examination
Number of subjects: 2113

Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 2113
Study: 29666296

Group type: EXPERIMENTAL
Intervention: Rilotumumab (20 mg/kg) and Bevacizumab (10 mg/kg) every 2 weeks
Number of subjects: 36
Study: 29666297

Group type: EXPERIMENTAL
Intervention: 30 mg of everolimus by mouth (PO) weekly
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 10 mg of everolimus PO daily
Number of subjects: 53
Study: 29666705

Group type: EXPERIMENTAL
Intervention: Aerobic exercise defined by CPET
Number of subjects: 48
Study: 29667014

Group type: EXPERIMENTAL
Intervention: Automatically computed QRS-score from 12-lead ECG
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Automatically computed QRS-score ≥ 9
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: QRS-score ≥ 3
Number of subjects: 1151
Study: 29667940

Group type: EXPERIMENTAL
Intervention: Saphenous nerve block with 10 mL 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo group receiving 10 mL saline
Number of subjects: 18
Study: 29668600

Group type: EXPERIMENTAL
Intervention: Clinical outcomes and genomic, epigenomic, and protein alterations analysis using a panel of 143 known cancer genes (Oncomine Comprehensive Assay).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Promoter methylation analysis for selected genes and tissue microarray for clinically relevant proteins (e.g., PD-L1, Erb-2, VEGFR2).
Number of subjects: 200
Study: 29669226

Group type: EXPERIMENTAL
Intervention: Gene therapy with autologous CD34+ cells transduced with the BB305 vector
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study: 29669391

Group type: EXPERIMENTAL
Intervention: Fostamatinib (a small molecule inhibitor of Syk)
Number of subjects: 450
Study: 29669562

Group type: EXPERIMENTAL
Intervention: Palliative sedation with monitoring using NeuroSense and ANI monitors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for pain/comfort assessment by patients (if possible)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caregivers' assessment of pain, awareness, and communication
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relatives' perception of the quality of the dying process
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Observational scales by trained investigators
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Video and audio registration
Number of subjects: 40
Study: 29669676

Group type: EXPERIMENTAL
Intervention: Mepilex-Border Post-Op (intervention group)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Conventional adhesive dressing (Cosmopor) (control group)
Number of subjects: 209
Study: 29669701

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice per day (oral) on a continuous daily dosing schedule for 21 days until disease progression, unacceptable toxicity, or patient refusal.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 20
Study: 29669707

Group type: EXPERIMENTAL
Intervention: Web-based decision tool incorporating the US MEC guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative surveys and semistructured qualitative interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thematic analysis of qualitative data from interviews and field observations
Number of subjects: 0
Study: 29669753

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg orally daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg orally daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ibrutinib (both doses)
Number of subjects: 14
Study: 29669934

Group type: EXPERIMENTAL
Intervention: Kisspeptin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH)
Number of subjects: 15
Study: 29669936

Group type: EXPERIMENTAL
Intervention: HPV-16 E7-specific TCR T cell therapy
Number of subjects: 0
Study: 29669944

Group type: EXPERIMENTAL
Intervention: Lupus low density granulocytes (LDGs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 29669947

Group type: EXPERIMENTAL
Intervention: ASCT + CTL019
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CTL019
Number of subjects: 10
Study: 29670545

Group type: EXPERIMENTAL
Intervention: NU-AGE Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29670761

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q4W
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 29671186

Group type: EXPERIMENTAL
Intervention: Benzodiazepine-Free Cardiac Anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard benzodiazepine anesthesia
Number of subjects: 0
Study: 29671866

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation (IHV)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (standard weaning procedure)
Number of subjects: 31
Study: 29671921

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29672090

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 85
Study: 29672210

Group type: EXPERIMENTAL
Intervention: Contrast stress echocardiography (CSE)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Stress electrocardiogram (sECG)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rest BNP
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Abnormal sECG
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 400
Study: 29672676

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Number of subjects: 30
Study: 29672891

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks
Number of subjects: 100
Study: 29673046

Group type: EXPERIMENTAL
Intervention: Newly diagnosed type 2 diabetes
Number of subjects: 2
Study: 29673370

Group type: EXPERIMENTAL
Intervention: Early initiation of renal replacement therapy (RRT) within 6 hours
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard initiation of renal replacement therapy (RRT) by urgent indication
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Early RRT
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard RRT
Number of subjects: 118
Study: 29673379

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU/ml
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study: 29673381

Group type: EXPERIMENTAL
Intervention: Mobile phone message group (either text messages [SMS] or voice messages [VM])
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (weekly monitoring survey)
Number of subjects: 600
Study: 29673798

Group type: EXPERIMENTAL
Intervention: Transcutaneous CO-oximetry
Number of subjects: 0
Study: 29673890

Group type: EXPERIMENTAL
Intervention: FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin)
Number of subjects: 210
Study: 29673942

Group type: EXPERIMENTAL
Intervention: Tick-borne encephalitis (TBE) booster vaccine
Number of subjects: 119
Study: 29674306

Group type: EXPERIMENTAL
Intervention: DIABEO telemedicine system (physician-assisted telemedicine)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: DIABEO telemedicine system (nurse-assisted telemonitoring and teleconsultations)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Usual follow-up (control group)
Number of subjects: 696
Study: 29674323

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) for up to 7 days in CF participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control subjects (HCs)
Number of subjects: 0
Study: 29674365

Group type: EXPERIMENTAL
Intervention: 30 compressions and 2 s pause
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: 50 compressions and 5 s pause
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: 100 compressions and 10 s pause
Number of subjects: 552

Group type: COMPARATOR
Intervention: hands-only CPR
Number of subjects: 552
Study: 29674506

Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs (specifically miR-126-5p)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 141
Study: 29674852

Group type: EXPERIMENTAL
Intervention: Minimally invasive trans-iliac sacroiliac joint fusion using triangular titanium implants (TTI)
Number of subjects: 103
Study: 29675856

Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE, 1 μm) combined with carbachol (CA, 3 μm)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PKC inhibitor GF 109203X
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rho kinase inhibitor Y-27632
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined intervention of PKC inhibitor and Rho kinase inhibitor
Number of subjects: 28
Study: 29676033

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29676049

Group type: EXPERIMENTAL
Intervention: Diet-induced moderate weight loss (5% weight loss)
Number of subjects: 11
Study: 29676557

Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 364

Group type: COMPARATOR
Intervention: Practice-based collaborative care
Number of subjects: 364
Study: 29677187

Group type: EXPERIMENTAL
Intervention: Prolonged and exclusive breastfeeding promotion modelled on the Baby-Friendly Hospital Initiative
Number of subjects: 13557

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for ≥3 months
Number of subjects: 13557

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 13557
Study: 29677353

Group type: EXPERIMENTAL
Intervention: Intravitreal delivery (1 × 10^12 vg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Subretinal delivery (1 × 10^10 vg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Subretinal delivery (high dose: 1 × 10^12 vg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Subretinal delivery (low dose: 1 × 10^11 vg)
Number of subjects: 22
Study: 29677606

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 40
Study: 29678146

Group type: COMPARATOR
Intervention: Adjuvant S-1 chemotherapy
Number of subjects: 375

Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Chemotherapy including S-1 (IS)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Chemotherapy not including S-1 (NIS)
Number of subjects: 375
Study: 29678145

Group type: EXPERIMENTAL
Intervention: PET and staging laparoscopy (SL)
Number of subjects: 543
Study: 29678183

Group type: EXPERIMENTAL
Intervention: Portfolio diet based on several food items with suggested anti-inflammatory effects
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study: 29678204

Group type: COMPARATOR
Intervention: Low pressure irrigation
Number of subjects: 2447

Group type: COMPARATOR
Intervention: Soap treatment
Number of subjects: 2447
Study: 29678409

Group type: EXPERIMENTAL
Intervention: Phototherapy for neonatal hyperbilirubinemia
Number of subjects: 135

Group type: COMPARATOR
Intervention: No phototherapy
Number of subjects: 135
Study: 29678476

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus Lapatinib (intravenous cabazitaxel 20 mg/m²)
Number of subjects: 11
Study: 29678669

Group type: EXPERIMENTAL
Intervention: Oncogeriatric consultation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Geriatric screening
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Consultation report
Number of subjects: 31
Study: 29678802

Group type: EXPERIMENTAL
Intervention: Phone call enrollment
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Chat/Instant Message (IM) enrollment
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Fully automated enrollment process
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Overall enrollment process modifications
Number of subjects: 719

Group type: COMPARATOR
Intervention: Automated process vs. phone interaction
Number of subjects: 719
Study: 29678801

Group type: EXPERIMENTAL
Intervention: Stigma prevalence
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Stigma association with glycemic control
Number of subjects: 380
Study: 29678804

Group type: EXPERIMENTAL
Intervention: iWaWa treatment (8 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: wait-list control group
Number of subjects: 89
Study: 29678813

Group type: EXPERIMENTAL
Intervention: Nuisance bleeding (NB) documented in 1357 patients (20.0%) with an incidence rate of 14.8 events per 100 person-years.
Number of subjects: 6771

Group type: EXPERIMENTAL
Intervention: Nuisance bleeding (NB)
Number of subjects: 6771
Study: 29678971

Group type: EXPERIMENTAL
Intervention: Gamified intervention (StepSmart Challenge) involving a pedometer competition and material rewards
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gamified intervention
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gamified Behaviour Change Techniques
Number of subjects: 19
Study: 29679103

Group type: EXPERIMENTAL
Intervention: HLA-A*24 positivity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SLC30A8 CT or TT genotypes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BMI more than or equal to the group median (23.9 kg/m²)
Number of subjects: 40
Study: 29680101

Group type: EXPERIMENTAL
Intervention: CDI-DaySyms (13-item draft daily diary)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cognitive interviews (stage 2)
Number of subjects: 34
Study: 29680471

Group type: EXPERIMENTAL
Intervention: NIRS monitoring
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: aEEG monitoring
Number of subjects: 127
Study: 29680676

Group type: EXPERIMENTAL
Intervention: Opioid users
Number of subjects: 437

Group type: COMPARATOR
Intervention: Alcohol detoxification seekers
Number of subjects: 437
Study: 29680811

Group type: EXPERIMENTAL
Intervention: Simulation-based education (high-fidelity simulation)
Number of subjects: 0
Study: 29680880

Group type: EXPERIMENTAL
Intervention: PRO-122 (preservative-free fixed combination)
Number of subjects: 51

Group type: COMPARATOR
Intervention: KOF (0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PRO-122
Number of subjects: 51

Group type: COMPARATOR
Intervention: KOF
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PRO-122 and KOF
Number of subjects: 51
Study: 29680881

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg daily
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1430
Study: 29681462

Group type: EXPERIMENTAL
Intervention: Onclarity HPV assay
Number of subjects: 33858
Study: 29681490

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (120 mg twice daily on days one to seven; 240 mg twice a day thereafter)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Number of subjects: 22
Study: 29681762

Group type: EXPERIMENTAL
Intervention: Posttreatment (POST) group with increased p53 nuclear/cytoplasmic (N/C) ratio
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Matched pairs (MP) group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pretreatment (PRE) group
Number of subjects: 60
Study: 29681866

Group type: EXPERIMENTAL
Intervention: Deep-brain stimulation (DBS) to the nucleus accumbens (NAcc)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DBS to the NAcc
Number of subjects: 6
Study: 29681973

Group type: EXPERIMENTAL
Intervention: Massage Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abdominal Hypopressive Gymnastics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Massage Therapy and Abdominal Hypopressive Gymnastics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29681977

Group type: EXPERIMENTAL
Intervention: 4-Week Intervention
Number of subjects: 0
Study: 29682131

Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint used for about 20 hours over a 4-month period
Number of subjects: 112

Group type: COMPARATOR
Intervention: Noninvasive therapy using a biostimulation laser over 12 sessions performed every second day
Number of subjects: 112
Study: 29682277

Group type: EXPERIMENTAL
Intervention: Cat-PAD (6 nmol) administered via four monthly injections
Number of subjects: 19
Study: 29682294

Group type: EXPERIMENTAL
Intervention: DuraGraft treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 0
Study: 29682332

Group type: COMPARATOR
Intervention: EGFR inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: ALK inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-PD1 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 29682773

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (higher daily doses)
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Adrenal crisis (AC)
Number of subjects: 2034

Group type: COMPARATOR
Intervention: Demographics and clinical characteristics
Number of subjects: 2034

Group type: COMPARATOR
Intervention: Causes of death
Number of subjects: 2034
Study: 29683544

Group type: EXPERIMENTAL
Intervention: High-dosed folate supplements (5 mg folic acid per day)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Iron supplements (200 mg ferrous sulphate per day)
Number of subjects: 318
Study: 29683562

Group type: EXPERIMENTAL
Intervention: Oral osimertinib 80 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) osimertinib 100 μg microtracer dose
Number of subjects: 10
Study: 29683703

Group type: EXPERIMENTAL
Intervention: STAMP (anxiety sensitivity reduction-smoking cessation intervention)
Number of subjects: 529

Group type: COMPARATOR
Intervention: SCP (standard smoking cessation intervention)
Number of subjects: 529
Study: 29683790

Group type: EXPERIMENTAL
Intervention: Carboxyamidotriazole orotate (CTO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study: 29683984

Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PAL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Single-Vision Lenses (SVL)
Number of subjects: 64
Study: 29684022

Group type: EXPERIMENTAL
Intervention: Combination therapy of ceftriaxone and azithromycin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Monotherapy with ceftriaxone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination therapy of azithromycin and cefexime
Number of subjects: 105

Group type: COMPARATOR
Intervention: Monotherapy with azithromycin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 105
Study: 29684662

Group type: EXPERIMENTAL
Intervention: Hypertensives
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Physicomechanical factors
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mechanical endothelial injury
Number of subjects: 41
Study: 29684739

Group type: EXPERIMENTAL
Intervention: Global Land Data Assimilation System (GLDAS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Climate Hazards Group InfraRed Precipitation with Stations (CHIRPS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Weather-station derived estimates
Number of subjects: 8

Group type: COMPARATOR
Intervention: Earth Observation (EO) derived estimates
Number of subjects: 8
Study: 29684764

Group type: EXPERIMENTAL
Intervention: Higher anxiety and higher perceptions that peers drink heavily
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Higher depression and perceptions of peers' drinking
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Attitudes that peers approve of heavy drinking
Number of subjects: 1254
Study: 29685114

Group type: EXPERIMENTAL
Intervention: DAR-901
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0